ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 998 • 2014 ACR/ARHP Annual Meeting

    β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10

    Georg Pongratz1, Clemens Wiest2, Madlen Melzer2 and Rainer Straub3, 1Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, 2University Hospital Regensburg, Regensburg, Germany, 3Internal Medicine, University Hospital Regensburg, Regensburg, Germany

    Background/Purpose Splenic B cells from collagen-induced arthritis (CIA) mice react to a β2-adrenoceptor (AR) stimulus with increased IL-10 production and adoptive transfer of these cells…
  • Abstract Number: 997 • 2014 ACR/ARHP Annual Meeting

    Explore Translational Pharmacokinetics/Pharmacodynamics Response/Efficacy Relationship of a Novel Bruton’s Tyrosine Kinase Inhibitor in Rat Collagen-Induced Arthritis Model

    Jie Zhang-Hoover1, Erica Leccese1, Kalyan Chakravarthy2, Ian Knemeyer2, Jos Lommerse2, Marianne Spatz2, Francois Gervais3, Raquel Sevilla4, Jian Liu5, Ronald Kim5, Sachin Lohani5, Kevin Matthew Maloney5, Joseph Kozlowski5 and Alexandra Hicks2, 1Pharmacology, Merck Research Laboratories, Boston, MA, 2Merck Research Laboratories, Boston, MA, 3Cell Pathways and Proteins, Merck & Co., Boston, MA, 4Imaging Group, Merck Research Laboratories, Boston, MA, 5Merck Research Laboratories, Rahway, NJ

    Background/Purpose: Abnormal B cell activation is an essential part of autoimmune inflammation. B cell depletion is proven to be an efficacious treatment in patients as…
  • Abstract Number: 996 • 2014 ACR/ARHP Annual Meeting

    Memory B Cell Subtype Modulation in Patients with Rheumatoid Arthritis

    Zafar Mahmood1, Marc Schmalzing2, Thomas Dörner3 and Hans-Peter Tony2, 1Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, 2Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, 3Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany

    Background/Purpose . Memory B cells have been shown to play important roles in the pathogenesis of rheumatoid arthritis (RA). With the advent of B cell…
  • Abstract Number: 995 • 2014 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Patients Have Alterations in Inherently Autoreactive 9G4+ B-Cell Subpopulations in Peripheral Blood

    Rita A. Moura1,2, Maria J. Leandro3, Venkat Reddy1, João E. Fonseca2,4 and Geraldine Cambridge3, 1Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 2Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 3Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 4Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon, Portugal

    Background/Purpose B-cells utilizing the VH-region immunoglobulin gene VH4-34 produce natural autoreactive antibodies. The rat monoclonal antibody 9G4 recognizes B-cells with VH4-34-encoded B-cell receptors (9G4+ B-cells)…
  • Abstract Number: 994 • 2014 ACR/ARHP Annual Meeting

    IL-7 Modulates B Cell Immunoglobulin Isotype Production and Increases B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Synovial Fibroblasts from Osteoarthritis (OA) and Rheumatoid Arthritis (RA) Patients

    Georg Pongratz1, Stephan Kuhn2, Madlen Melzer2, Torsten Lowin2 and Rainer Straub3, 1Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, 2University Hospital Regensburg, Regensburg, Germany, 3Internal Medicine, University Hospital Regensburg, Regensburg, Germany

    Background/Purpose Interleukin(IL)-7 is increased in synovial fluid from rheumatoid arthritis (RA) patients as compared to osteoarthritis (OA) patients and has been attributed a proinflammatory role,…
  • Abstract Number: 993 • 2014 ACR/ARHP Annual Meeting

    Anti-Citrullinated Proteins Antibodies Promote Synovial Fibroblast Migration in Rheumatoid Arthritis

    Meng Sun1, Vijay Joshua1, Aase Haj Hensvold1, Sergiu-Bogdan Catrina2, Lars Klareskog3, Vivianne Malmström4, Heidi Wähämaa1 and Anca I Catrina1, 1Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Molecular Medicine and Surgery, Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, 4Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose The presence of anti-citrullinated proteins antibodies (ACPAs) in RA is associated with aggressive disease phenotype and bone destruction. As synovial fibroblasts (SFs) are considered…
  • Abstract Number: 992 • 2014 ACR/ARHP Annual Meeting

    Differential Antigen-Presenting B-Cell Phenotype from Synovial Microenvironment of Rheumatoid Arthritis and Psoriatic Arthritis Patients

    Estefania Armas-Gonzalez1, Ana Diaz-Martin1, María Jesús Dominguez-Luis2, Maria Teresa Arce-Franco1, Ada Herrera-Garcia1, Vanesa Hernandez1, Alicia Usategui3, Jose L. Pablos4, Juan D. Cañete5, Sagrario Bustabad1 and Federico Díaz-González1, 1Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 2Center of Biomedical Research of the Canary Islands, University of La Laguna, Tenerife, Spain, 3Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 4Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 5Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain

    Background/Purpose The systemic depletion of B cells induced by mabthera, a monoclonal antibody against human CD20, has shown to be an effective therapy for controlling…
  • Abstract Number: 991 • 2014 ACR/ARHP Annual Meeting

    The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis

    Cecile Gamonet1, Marina Deschamps2, Sandrine Marion3, Philippe Saas4, Gilles Chioccha3, Christophe Ferrand4 and Eric Toussirot5,6, 1INSERM UMR1098, Etablissement Français du Sang / Université de Franche Comté, Besançon, France, 2INSERM UMR1098 / Etablissement Français du Sang/ Université de Franche Comté, Besançon, France, 3Chronic Inflammation and Immune System Labex Inflamex, Université Versailles Saint Quentin, Montigny le Bretonneux, France, 4Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, 5Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, 6Rheumatology, University hospital, Besançon, France

    Background/Purpose: the identification of predictive factors for the response, or alternatively factors for resistance to biological agents is a relevant goal in the management of…
  • Abstract Number: 961 • 2014 ACR/ARHP Annual Meeting

    Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study

    John G. Hanly for the Systemic Lupus International Collaborating Clinics1, Aidan O'Keeffe2, Li Su3, Murray B. Urowitz4, Juanita Romero-Diaz5, Caroline Gordon6, Sang-Cheol Bae7, Sasha R Bernatsky8, Ann E. Clarke9, Daniel J. Wallace10, Joan T. Merrill11, David A. Isenberg12, Anisur Rahman13, Ellen M. Ginzler14, Paul Fortin15, Dafna D. Gladman4, Jorge Sanchez-Guerrero16, Michelle Petri17, Ian Bruce18, Mary Anne Dooley19, Rosalind Ramsey-Goldman20, Cynthia Aranow21, Graciela S. Alarcon22, Barri Fessler23, Kristjan Steinsson24, Ola Nived25, Gunnar Sturfelt25, Susan Manzi26, Munther A. Khamashta27, Ronald F. van Vollenhoven28, Asad Zoma29, Manuel Ramos-Casals30, Guillermo Ruiz-Irastorza31, S. Sam Lim32, Thomas Stoll33, Murat Inanc34, Kenneth C. Kalunian35, Diane L. Kamen36, Peter Maddison37, Christine A. Peschken38, Søren Jacobsen39, Anca Askanase40, Jill P. Buyon41, Chris Theriault42, Kara Thompson42 and Vernon Farewell3, 1Division of Rheumatology, Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, Canada, 2MRC Biostatistics Unit, Institute of Public Heath, Cambridge, United Kingdom, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion, Mexico city, Mexico, 6Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 8Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, Canada, 9Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, 10Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, 11Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 13Centre for Rheumatology Research, University College London, London, United Kingdom, 14Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, 15Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, 16Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 17Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 18Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 19Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 20Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, 21Feinstein Institute for Medical Research, Mahasset, NY, 22Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 23Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 24Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland, 25Department of Rheumatology, University Hospital Lund, Lund, Sweden, 26Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 27Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 28Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 29Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, 30Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, 31Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, 32Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 33Kantonsspital Geissbergstr, Schaffhausen, Switzerland, 34Division of Rheumatology, Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, 35UCSD School of Medicine, La Jolla, CA, 36Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 37Ysbyty Gwynedd Bangor, North Wales, United Kingdom, 38Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 39Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 40Columbia University Medical Center, New York, NY, 41Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 42Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada

    Background/Purpose: Improved immunosuppressive therapies have changed the treatment of lupus nephritis (LN) over the past decade. We examined the outcome of LN with current standard…
  • Abstract Number: 960 • 2014 ACR/ARHP Annual Meeting

    Allogeneic Mesenchymal Stem Cell Transplantation for Lupus Nephritis Patients Refractory to Conventional Therapy

    Dandan Wang1, Huayong Zhang1, Xuebing Feng2 and Lingyun Sun2, 1The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

    Background/Purpose Allogeneic mesenchymal stem cell transplantation (MSCT) has been shown to be clinically efficacious in the treatment of various autoimmune diseases. Here we analyzed the…
  • Abstract Number: 977 • 2014 ACR/ARHP Annual Meeting

    Randomized Clinical Trial of a Patient and Provider Intervention for Managing Osteoarthritis in Veterans

    Kelli D. Allen1,2, Hayden B. Bosworth3,4, Amy Jeffreys1, Cynthia Coffman3,5, Santanu Datta4,6, Jennifer McDuffie1,7, Eugene Oddone3,4, Jennifer Strauss1,8 and William S. Yancy Jr.1,4, 1Health Services Research, Durham VA Medical Center, Durham, NC, 2Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Health Services Research, Durham VA Medical Center and Duke University Medical Center, Durham, NC, 4Department of Medicine, Division of General Internal Medicine, Duke University Medical Center, Durham, NC, 5Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, 6Health Services Reserach, Durham VA Medical Center and Duke University Medical Center, Durham, NC, 7Medicine, Duke University Medical Center, Durham, NC, 8Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC

    Background/Purpose: Adequate management of osteoarthritis (OA) requires both medical and behavioral strategies. However, some recommended therapies are under-utilized in clinical settings, and there is low…
  • Abstract Number: 976 • 2014 ACR/ARHP Annual Meeting

    Measurement Properties of the Health Assessment Questionnaire Disability Index (HAQ-DI) in Patients with Generalized Osteoarthritis (GOA)

    Nienke Cuperus1, Elien A.M. Mahler2, Thea Vliet Vlieland3, Thomas Hoogeboom4 and Cornelia H.M. van den Ende5, 1Rheumatology Department, Sint Maartenskliniek, Nijmegen, Netherlands, 2Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 3Dept of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands, 4Department of Epidemiology, CAPHRI school for public health and primary care, CCTR centre for Care Technology Research, Maastricht University, Maastricht, Netherlands, 5Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: The involvement of multiple joints is common in osteoarthritis (OA), often referred to as generalized OA (GOA). Individuals with GOA typically suffer from limitations…
  • Abstract Number: 975 • 2014 ACR/ARHP Annual Meeting

    Chronic Pain Predicts Reduced Physical Activity in a Large Population Cohort Study

    Kathryn Remmes Martin, Marcus Beasley, Gary J. Macfarlane and Daniel Whibley, Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom

    Background/Purpose: Chronic musculoskeletal pain (CP) is associated with reduced levels of physical activity (PA), however few studies have examined the prospective nature of CP on…
  • Abstract Number: 974 • 2014 ACR/ARHP Annual Meeting

    Obesity Paradox in Osteoarthritis Progression – What Effects Are We Measuring?

    Qiong Louie-Gao1, Hyon K. Choi2, David T. Felson1,3, Tuhina Neogi4, Uyen Sa D.T. Nguyen5,6, Na Lu2 and Yuqing Zhang2, 1Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, 4Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 5Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 6Clinical Epidemiology Research &Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: While obesity is a well-established risk factor for incident knee osteoarthritis (OA), it has a null association with OA progression.  Among various potential explanations…
  • Abstract Number: 973 • 2014 ACR/ARHP Annual Meeting

    Relation of Pelvic Drop during Walking to Risk of Incident Medial Knee Osteoarthritis: The Multicenter Osteoarthritis Study

    K. Douglas Gross1,2, Emily K. Quinn3, Michael C. Nevitt4, James C. Torner5, Cora E. Lewis6 and David T. Felson7, 1Physical Therapy, MGH Institute of Health Professions, Boston, MA, 2Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 3Clinical Epidemiology Unit, Boston University, Boston, MA, 4Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, 5Epidemiology, University of Iowa, Iowa City, Iowa City, IA, 6Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, 7Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: During walking, the contralateral pelvis tends to drop as the weight bearing limb enters midstance. If excessive, pelvic drop (PD) can result in increased…
  • « Previous Page
  • 1
  • …
  • 1984
  • 1985
  • 1986
  • 1987
  • 1988
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology